Insight Molecular Diagnostics (IMDX) Non-Current Assets (2015 - 2026)

Insight Molecular Diagnostics (IMDX) has 12 years of Non-Current Assets data on file, last reported at $8.9 million in Q1 2026.

• Quarterly Non-Current Assets rose 24.54% year-over-year to $8.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.9 million (up 24.54% YoY) and the FY2025 annual result came in at $9.2 million, up 46.27% from the prior year.
• Non-Current Assets declined to $8.9 million in Q1 2026 per IMDX's latest filing, from $9.2 million in the prior quarter.
• The five-year high for Non-Current Assets was $121.7 million in Q2 2022, with the low at $5.4 million in Q4 2023.
• Average Non-Current Assets over 5 years is $51.9 million, with a median of $64.7 million recorded in 2023.
• Year-over-year, Non-Current Assets surged 82.98% in 2022 and tumbled 92.71% in 2023.
• Insight Molecular Diagnostics' Non-Current Assets stood at $74.6 million in 2022, then plunged by 92.71% to $5.4 million in 2023, then gained by 16.34% to $6.3 million in 2024, then surged by 46.27% to $9.2 million in 2025, then retreated by 3.66% to $8.9 million in 2026.
• Business Quant data shows IMDX's Non-Current Assets at $8.9 million in Q1 2026, $9.2 million in Q4 2025, and $6.5 million in Q3 2025.